Literatur

Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie (DGHO) et al.: Follikuläres Lymphom. Stand: Juli 2025. Online unter: Follikuläres Lymphom — Onkopedia

Lorenzo Falchi et al. Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial, The Lancet, Volume 407, Issue 10524, 2026, Pages 161-173, https://doi.org/10.1016/S0140-6736(25)02360-8. 

Gloria Iacoboni, Franck Morschhauser; Building the future management of follicular lymphoma with T-cell–redirecting strategies. Blood 2025; 145 (2): 170–175. doi: https://doi.org/10.1182/blood.2024025699

John P. Leonard et al. Lenalidomide Plus Rituximab for Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: 5-Year Follow-up and Subgroup Analyses From the Phase III AUGMENT Trial. J Clin Oncol 44, 1483-1489(2026). DOI:10.1200/JCO-25-01770